VIVO Cannabis Inc. V.PDA

Primary Symbol: VVCIF

Healthcare Drug Manufacturers - Specialty & Generic

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.

OTCQB:VVCIF - Post by User

VIVO Cannabis Inc. > 100 years combined experience in pharmaceuticals gets $0.13

<< Previous

Bullboard Posts

Next >>

Comment by 1hot-techwomanon May 26, 2021 4:50pm

125 Views

Post# 33272403

RE:100 years combined experience in pharmaceuticals gets $0.13

1hot-techwoman wrote: You guys have to stand by Good ole Barry on your slogans at AGM's " We are professionals not Cowboys...LOL "

Could you Imagine is half the bullshite that was posted in 2019 comes true for you guys?? But alas you wll be bought out for peanuts because you are old, pompus fat exec's that have already made your money and have no drive !!! Pretty obvious when you dont even have the balls to face questions from shareholders and would rather put up those video presentations !!! Sad is understatement !! Bring on 2022....LOL

VIVO Cannabis

VIVO Cannabis (TSXV:VIVO) is a Canadian licensed producer of premium medical-grade cannabis with over 100 years combined experience in international pharmaceuticals. The company offers high-quality cannabis and premium medical products through its Fireside, Beacon Medical, and Lumina brands.

In March of 2019, VIVO received approval for expansion at both its British Columbia and Ontario facilities, adding 4,000 kg of production. This brings the company’s total annual production to 8,000 kg by the end of 2019 and expects to increase that to 13,500 kg by 2020.

VIVO is a leader in the Canadian medical market with the company’s wholly owned Harvest Medicine operating five clinics in four provinces with over 27,000 patients. In Europe, the company has received a wholesale licence in Germany and already has 30,000 patients.

By 2022, the company expects to be making $350 million in domestic and international medical cannabis sales revenue with an additional $150 million in recreational sales. With a net selling price of $7.70 per gram, VIVO premium cannabis remains within the top tier of the industry.